We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of Endoscopic Radiofrequency Ablation Versus Photodynamic Therapy for Inoperable Cholangiocarcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01739465
Recruitment Status : Unknown
Verified February 2013 by Huihong Liang, Guangzhou Medical University.
Recruitment status was:  Recruiting
First Posted : December 3, 2012
Last Update Posted : February 26, 2013
Sponsor:
Information provided by (Responsible Party):
Huihong Liang, Guangzhou Medical University

Brief Summary:
The purpose of this study is to compare endoscopic radiofrequency ablation with photodynamic therapy for inoperable cholangiocarcinoma

Condition or disease Intervention/treatment Phase
Cholangiocarcinoma Procedure: Self expanding metallic stent (SEMS) Procedure: Endoscopic radiofrequency ablation (ERFA) Procedure: Photodynamic therapy (PDT) Phase 2 Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Controlled Trial Comparing Endoscopic Biliary Radiofrequency Ablation With Photodynamic Therapy for Inoperable Cholangiocarcinoma
Study Start Date : November 2012
Estimated Primary Completion Date : December 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Endoscopy
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: Self expanding metallic stent (SEMS )placement only
Endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) would be performed to confirm the position and length of the biliary malignant. A self expanding metallic stent (SEMS) would be placed to bypass the site of narrowing
Procedure: Self expanding metallic stent (SEMS)
Self expanding metallic stent
Experimental: Endoscopic radiofrequency ablation plus SEMS
Endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) would be performed to confirm the position and length of the biliary malignant. The radiofrequency ablation (RFA) catheter (EMcision, London, United Kingdom) would be placed under fluoroscopic guidance across the biliary stricture. Radiofrequency energy will be delivered to the malignant site. After that,A self expanding metallic stent (SEMS) would be placed to bypass the site of narrowing
Procedure: Self expanding metallic stent (SEMS)
Self expanding metallic stent
Procedure: Endoscopic radiofrequency ablation (ERFA)
Endoscopic radiofrequency ablation
Experimental: Photodynamic therapy plus SEMS
Photofrin is injected 3 days prior to laser activation of the agent.Endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) will be carried out to determine the length and positon of the biliary malignant. Delivery Fiber used along with the laser system to activate the photosensitizing agent and induce tumor tissue necrosis. A self expanding metallic stent (SEMS) will be placed the site of biliary narrowing
Procedure: Self expanding metallic stent (SEMS)
Self expanding metallic stent
Procedure: Photodynamic therapy (PDT)
Photodynamic therapy



Primary Outcome Measures :
  1. stent patency [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. overall survival rate [ Time Frame: 3 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ 18 years old
  • Pathologically or radiologically confirmed biliary malignant
  • Inoperability by staging

Exclusion Criteria:

  • Cholangiocarcinoma with widespread metastasis
  • Coagulopathy (INR > 2.0 or prothrombin time > 100 sec or platelet count < 50,000)
  • Prior SEMS placement
  • Pregnancy
  • Eastern Cooperative Oncology Group (ECOG) performance status ≥ 3 )
  • Life expectancy < 3months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01739465


Contacts
Contact: Huihong Liang, MD +86-20-34153043 beanth@163.com

Locations
China, Guangdong
The Second Hospital of Guangzhou Medical College Not yet recruiting
Guangzhou, Guangdong, China, 510260
Contact: Huihong Liang, MD    +86-188-2648-8232    beanth@163.com   
The second hospital of Guangzhou Medical college Recruiting
Guangzhou, Guangdong, China, 510260
Contact: Huihong Liang, Doctorial    +86-188-2648-8232    beanth@163.com   
Principal Investigator: Huihong Liang, Doctoral         
Sponsors and Collaborators
Guangzhou Medical University

Responsible Party: Huihong Liang, Associated Professor, Guangzhou Medical University
ClinicalTrials.gov Identifier: NCT01739465     History of Changes
Other Study ID Numbers: RFA2012
First Posted: December 3, 2012    Key Record Dates
Last Update Posted: February 26, 2013
Last Verified: February 2013

Keywords provided by Huihong Liang, Guangzhou Medical University:
Cholangiocarcinoma
Pathologic
Digestive System
Neoplasms
Neoplasms by Site
Digestive System Diseases
Bile Duct Diseases
Biliary Tract Diseases
Pathological Conditions
Constriction
Adenocarcinoma
Carcinoma

Additional relevant MeSH terms:
Cholangiocarcinoma
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms